We previously showed that the augmented levels of endogenous angiotensin II (Ang II) contribute to vascular smooth muscle cell (VSMC) hypertrophy through the transactivation of growth factor receptors in spontaneously hypertensive rats. Resveratrol (RV), a polyphenolic component of red wine, has also been shown to attenuate Ang II-evoked VSMC hypertrophy, however, the molecular mechanism mediating this response is obscure. The present study is therefore undertaken to examine if RV could prevent Ang II-induced VSMC hypertrophy through the transactivation of growth factor receptor and associated signaling pathways. Ang II treatment of VSMC enhanced the protein synthesis which was attenuated towards control levels by RV pre-treatment as well as by the inhibitors of NADPH oxidase, c-Src, and growth factor receptors. Furthermore, RV pre-treatment also inhibited the enhanced levels of superoxide anion, NADPH oxidase activity, the increased expression of NADPH oxidase subunits and phosphorylation of c-Src, EGF-R, PDGE-R, ERK1/2, and AKT1/2. In conclusion, these results indicate that RV attenuates Ang II-induced VSMC hypertrophy through the inhibition of enhanced oxidative stress, activation of c-Src, growth factor receptors and MAPK/AKT signaling. It may be suggested that RV could be used as a therapeutic agent in the treatment of vascular complications associated with hypertension and hypertrophy.
to vascular remodeling that is attributed to several vascular diseases such as atherosclerosis, restenosis, and hypertension (Touyz 2005) . Angiotensin II (Ang II), the main vasoactive peptide of the renin-angiotensin-aldosterone system (RAAS), regulates a variety of pathophysiological functions including high blood pressure, VSMC hyperproliferation, and hypertrophy (Atef and Anand-Srivastava 2014; Beaucage and Moreau 2004; Bouallegue et al. 2009 ) by the activation of various signaling mechanisms including adenylyl cyclase/cAMP, phosphatidyl inositide 3-kinases (PI3K), mitogen-activated protein kinase (MAPK), and tyrosine kinase pathways (Gomez Sandoval and Anand-Srivastava 2011; Gusan and Anand-Srivastava 2013; Nakashima et al. 2008) . At the cellular level, Ang II elicits these molecular signals by interacting with two distinct subtypes of receptor, designated AT 1 and AT 2 (Timmermans et al. 1993 ). Both AT 1 and AT 2 receptors are present in heart muscle as well as in cardiomyocytes and mediate the physiological effects of Ang II (Bkaily et al. 2005; Booz and Baker 1996) . In addition, AT 1 receptor subtype is also present in rat vascular tissues, however, a small proportion of AT 2 receptors are present in rat aorta, (Chang and Lotti 1991) . Most of the pathophysiological effects of Ang II are mediated by the activation of AT 1 receptors. Ang II has also been shown to increase the oxidative stress due to the production of reactive oxygen species (ROS) through the activation of NADPH oxidase (Griendling et al. 1994; Seshiah et al. 2002) . ROS through the activation of various downstream kinases, including MAPK and the serine/threonine kinase AKT (also known as protein kinase B or PKB), are implicated in Ang II-induced hypertrophic response of VSMCs (Ushio-Fukai et al. 1998; Ushio-Fukai et al. 1999) . We also reported that enhanced levels of endogenous Ang II in VSMC from spontaneously hypertensive rat (SHR) D r a f t 4 through oxidative stress, transactivation of growth factor receptors; insulin-like growth factor receptor (IGF-R), epidermal growth factor receptor (EGF-R), and platelet-derived growth factor receptor (PDGF-R) and associated MAPK signaling, contributes to VSMC hypertrophy (Atef and Anand-Srivastava 2016a) .
Resveratrol (RV), an antioxidant and an important polyphenolic component of red wine has been shown to attenuate the development of hypertension in SHR and other experimental models of hypertensive rats (Bhatt et al. 2011) as well as cardiac hypertrophy (Petrovski et al. 2011 ). In addition, RV has also been shown to attenuate Ang II-evoked VSMC hypertrophy through the inhibition of AKT/protein kinase B and p70 S6 kinase phosphorylation (Haider et al. 2002) . However, whether RV inhibits Ang II-induced VSMC hypertrophy through the attenuation of growth factor receptor transactivation and associated signaling pathways that have been implicated in hypertrophy of VSMC has not been explored. Therefore, the present study was undertaken to investigate the effect of RV on Ang II-induced VSMC hypertrophy and to delineate the role of the transactivation of growth factor receptor and associated signaling in the antihypertrophic effect of RV.
We showed that RV inhibits Ang II-induced VSMC hypertrophy through its ability to attenuate oxidative stress, activation of c-Src, growth factor receptors and MAPK/AKT signalling pathways.
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Materials and Methods
Materials
Resveratrol (3,4′,5-trihydroxy-trans-stilbene), Angiotensin II (human), epidermal growth factor receptor (EGF-R) inhibitor AG1478, platelet-derived growth factor receptor (PDGF-R) inhibitor AG1295, c-Src inhibitor PP2, inactive analog for Src inhibitor PP3 and inhibitor of NADPH oxidase diphenleneiodonium (DPI) were purchased from Sigma-Aldrich Chemical Co.
(St Louis, Missouri, USA). Western blotting primary antibodies against EGF-R (sc-373746), p- 
Methods
Animal preparation
Male Sprague Dawley (SD) rats (225 to 230 g, ten-week-old) purchased from Charles River (Saint-Constant, Québec, Canada) were maintained on a standard rat chow diet and tap water ad libitum with a 12:12 h light:dark cycle in a quiet environment for two weeks (acclimatization). The rats were anesthetized by CO 2 exposure and then euthanized by decapitation. The aortas were dissected out and used for cell culture as described previously (Anand-Srivastava et al. 1982) . All the animal procedures used in the present study were 
Cell culture, incubation, and cell lysis
Aortic VSMCs from twelve-week-old SD rats were cultured as described previously (Anand-Srivastava et al. 1982) . The cell purity was determined by immunofluorescence using α-actin as described previously (Liau and Chan 1989 M Ang II, a concentration previously shown to be effective in VSMC (Li and Anand-Srivastava 2012; Li et al. 2007) . After 24 h incubation, the cells were washed twice with ice-cold phosphate buffer saline (PBS) and lysed in a 200 µl buffer containing 25 mM Tris-HCl (pH 7.5), 25 mM NaCl, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 10 mM sodium pyrophosphate, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 µg/mL aprotinin, 1% Triton X-100, 0.1% sodium dodecyl sulfate, and 0.5 µg/mL leupeptin on ice. The cell lysates were centrifuged at 12000 g for 15 min at 4°C, and the supernatants were used for Western blot analysis. Protein concentrations were measured with a Bradford assay (Bradford 1976) .
Western blotting
The levels of protein expression and phosphorylation were determined by Western 
Protein/DNA ratio measurements
Cell hypertrophy was also assessed by calculating the ratio of total protein to genomic DNA (gDNA) content as described previously (McKay et al. 1998) . For this assessment, VSMCs were plated in six-well plates at a seeding density of 2 to 3 × 10 4 cells/well. After starvation by incubation in DMEM without FBS at 37°C as described above, VSMCs were pre-incubated in Scientific, Waltham, MA). The total protein content was estimated colorimetrically using the method described by Bradford (Bradford 1976) . Serial concentrations of calf thymus DNA and bovine serum albumin (BSA) were used for the calibration curves. 
Superoxide anion (O
NADPH oxidase activity determination
The activation of NADPH oxidase activity in the samples was assessed by adding 10 
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Statistical analysis
Results are expressed as means ± SE (Standard Error). Comparisons between groups
were made with one-way analysis of variance (ANOVA) followed by Bonferroni's post-hoc test using GraphPad Prism version 5 (GraphPad Software Inc., La Jolla, California, USA). A difference between groups was significant at p < 0.05. Figure 1 shows the effect of different concentrations of RV on Ang II-induced hypertrophy of aortic VSMC. As reported earlier (Haider et al. 2002) , Ang II enhanced the [ 3 H]-Leucine incorporation ( Figure 1A ) and protein/DNA ratio ( Figure 1B) Figure 1A ). Therefore, 30 µM RV was used for further studies.
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Results
RV inhibits Ang II-induced VSMC hypertrophy
RV inhibits Ang II-induced oxidative stress
Ang II has been shown to stimulate NADPH oxidases and produce reactive oxygen species (ROS) resulting in increased oxidative stress (Seshiah et al. 2002) . To investigate if Ang II-induced enhanced protein synthesis in VSMC is due to enhanced oxidative stress, the effect of DPI, an inhibitor of NADPH oxidase on protein synthesis was examined. As shown in Figure   2A , the protein synthesis in VSMC that was significantly augmented by Ang II treatment by about 70% was completely attenuated to control level by DPI pre-treatment. In addition, DPI also inhibited the protein synthesis in control cells by about 50%. To further examine if RVinhibits Ang II-induced hypertrophy through its ability to attenuate the enhanced oxidative stress, the effect of RV on the Ang II-mediated production of superoxide anion (O 2 -) and NADPH oxidase activity was examined. As reported earlier (Li et al. 2007) , Ang II enhanced the D r a f t production of O 2 -( Figure 2B ) and NADPH oxidase activity ( Figure 2C ) in VSMCs by about 100% and 75% respectively and RV pre-treatment attenuated completely the enhanced levels of O 2 -and NADPH oxidase activity to control levels. In addition, RV treatment decreased the basal levels of O 2 -and NADPH oxidase activity by about 25% and 40% respectively in control cells.
To further investigate if the inhibition of enhanced activity of NADPH oxidase induced by Ang II by RV is attributed to its ability to decrease the expression of different subunits of NADPH oxidase, the effect of RV pre-treatment on Ang II-stimulated enhanced expression of Nox-1, gp91 phox , Nox-4, and p47 phox were examined in VSMC. As shown in Figure 3A -D, Ang II treatment significantly enhanced the levels of Nox-1, gp91 phox , Nox-4, and p47 phox subunits by about 80%, 40%, 60% and 130% respectively which were almost completely attenuated by RV pre-treatment. On the other hand, the expression of Nox-1, gp91 phox , Nox-4, and p47 phox subunits
were not altered by RV treatment alone.
RV inhibits Ang II-induced c-Src activation
We previously showed the implication of c-Src activation in oxidative stress-induced 
RV inhibits Ang II-induced growth factor receptor activation
Ang II-stimulated transactivation of EGF-R was shown to play a crucial role in cardiovascular remodeling including cardiac hypertrophy (Peng et al. 2016) . We have shown recently that augmented levels of endogenous Ang II through the transactivation of growth factor receptors EGF-R and PDGF-R contribute to VSMC hypertrophy in SHR (Atef and AnandSrivastava 2014). Therefore, it was also important to examine the role of EGF-R and PDGF-R in Ang II-induced VSMC hypertrophy. To test these, the effects of AG1478, a specific inhibitor of EGF-R and AG1295, a specific inhibitor of PDGF-R on Ang II-induced enhanced protein synthesis were examined in VSMC. Figure 5A shows that Ang II-induced enhanced (≈ 60%) protein synthesis was completely attenuated to control levels by AG1478 and AG1295. In addition, both these inhibitors also inhibited protein synthesis in control cells by about 40-50%.
To gain insight into whether RV attenuates Ang II-mediated hypertrophy via inhibition of transactivation of EGF-R and PDGF-R in VSMC, we examined the effect of RV pre-treatment on Ang II-induced phosphorylation of EGF-R and PDGF-R in VSMC. Results shown in Figure   5B and C indicate that Ang II enhanced the phosphorylation of EGF-R and PDGF-R by about 200% and 70% respectively which were almost completely attenuated to control levels by RV D r a f t 14 pre-treatment. In addition, RV also decreased the phosphorylation of EGF-R and PDGF-R by about 35% and 65% respectively in control cells. On the other hand, the expressions of total EGF-R and PDGF-R was not altered by these treatments.
RV inhibits Ang II-induced ERK1/2 and AKT/PKB activation
Growth factor receptors (GFRs) have been shown to signal through MAPK and AKT pathways (Oda et al. 2005) . Since RV inhibits Ang II-induced activation of growth factor receptors, it was of interest to examine the effect of RV pre-treatment on Ang II-stimulated ERK1/2 and AKT1/2 activation. As reported earlier (Haider et al. 2002; Zhang et al. 2012 
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Discussion
The present study provides insight into the molecular mechanisms through which RV attenuates Ang II-induced hypertrophy of VSMC. Although, the inhibition of Ang II-induced AKT/protein kinase B (PKB) and p70 S6 kinase phosphorylation by RV, and the subsequent attenuation of hypertrophy of rat aortic VSMC has been shown earlier (Haider et al. 2002) , we
show for the first time that RV attenuates Ang II-stimulated VSMC hypertrophy through the inhibition of c-Src and growth factor receptor activation, the upstream signaling molecules of AKT pathway.
Growth factor receptor transactivation by G protein coupled receptor (GPCR) including
AT 1 receptor is well established (Daub et al. 1996; Gomez Sandoval et al. 2009; Itoh et al. 1993 ).
In addition, the enhanced activation of growth factor receptors EGF-R and PDGF-R exhibited by VSMC from SHR was also shown to be attributed to the enhanced levels of endogenous Ang II (Atef and Anand-Srivastava 2016a; Li et al. 2010; Sandoval et al. 2011) . Furthermore, the implication of EGF-R transactivation induced by endogenous Ang II has been shown to mediate VSMC hypertrophy in SHR (Atef and Anand-Srivastava 2014) . Consistent with results reported by others (Beaucage and Moreau 2004; Bokemeyer et al. 2000; Eguchi et al. 1998; Gao et al. 2006 ), we also show that Ang II enhanced the phosphorylation (activation) of both EGF-R and PDGF-R in VSMC and the activation of both EGF-R and PDGF-R contributes to Ang II-induced VSMC hypertrophy because the inhibition of EGF-R and PDGF-R by inhibitors AG1478 and RV has been reported to suppress Ang II-induced AKT/protein kinase B and subsequent hypertrophy in rat aortic VSMCs (Haider et al. 2002) . We also report that RV inhibits the enhanced phosphorylation of ERK1/2 and AKT1/2 induced by Ang II in VSMC. Ang II-induced activation of MAPK/ERK as well as AKT/PKB has been shown to mediate VSMC hypertrophy (Eguchi et al. 1998) . In addition, the role of these kinases in hypertrophy of VSMC from SHR has also been shown (Atef and Anand-Srivastava 2014; Servant et al. 1996) .We earlier showed that enhanced levels of endogenous Ang II in VSMC from SHR increase oxidative stress which through c-Src and growth factor receptor activation enhance MAPK and AKT activities and result in VSMC hypertrophy (Atef and Anand-Srivastava 2016a) . Taken together, it may be suggested that RV attenuates Ang II-induced VSMC hypertrophy through the inhibition of oxidative stress, c-Src, growth factor receptor activation and associated MAPK and AKT signaling pathways.
In conclusion, we provide evidence that RV-induced inhibition of c-Src and growth factor receptor activation may be the important signaling pathways through which it exhibits antihypertrophic effect. It may be suggested that RV could be used as a therapeutic agent in the treatment of vascular complications associated with hypertension and hypertrophy. Figure 5B), and PDGF-R phosphorylation ( Figure 5C ) were determined as described in the Methods section. In Figure 5B and Figure 5C , the upper panels are Western blot images. Data are expressed as % of the control group (CTL, taken as 100% Figure 6B ) were determined as described in the Methods section. In Figure 6A and Figure 
